×
About 7,267 results

ALLMedicine™ Acne Vulgaris Center

Research & Reviews  2,829 results

An overview of sarecycline for the treatment of moderate-to-severe acne vulgaris.
https://doi.org/10.1080/14656566.2020.1813279
Expert Opinion on Pharmacotherapy; Valente Duarte de Sousa IC

Sep 14th, 2020 - Sarecycline is a novel, tetracycline-class antibiotic specifically designed to treat inflammatory acne. It offers a narrow spectrum of activity (mainly against Cutinebacterium acnes), and it shows less in vitro activity than other tetracyclines ag...

Fighting acne for the fighting forces.
https://doi.org/10.12788/cutis.0057
Cutis Brahe C, Peters K

Sep 11th, 2020 - Acne vulgaris is one of the most common dermatologic diseases, ranging from comedonal or inflammatory papules to large, painful, disfiguring cysts. Numerous treatment approaches are available, each with their own risks and benefits that must be we...

Tolerability of tretinoin lotion 0.05% for moderate to severe acne vulgaris: a post hoc...
https://doi.org/10.12788/cutis.0059
Cutis Bhatia ND, Werschler WP et. al.

Sep 11th, 2020 - Acne vulgaris (acne) is the most common dermatologic disorder seen in black patients. However, data are lacking on the effects of treatments, such as topical retinoids. Acne in black patients is frequently associated with postinflammatory hyperpig...

The Effect of Isotretinoin on Oocyte Maturation in Adolescent Female Rats.
https://doi.org/10.1159/000510031
Gynecologic and Obstetric Investigation; Kacamak P, Ozogul C et. al.

Sep 7th, 2020 - Isotretinoin is used in acne vulgaris treatment for more than 20 years. Isotretinoin has serious side effects on many organs, but there are no comprehensive studies investigating its possible toxic effects on reproductive organs. Thus, we aimed to...

The Effects of Once-Daily Tretinoin 0.05% Lotion on Quality of Life in Patients with Mo...
https://doi.org/10.1007/s40257-020-00559-3
American Journal of Clinical Dermatology; Tyring SK, Kircik L et. al.

Sep 4th, 2020 - In two phase III clinical trials of patients with moderate-to-severe acne (NCT02932306, NCT02965456), tretinoin 0.05% lotion reduced inflammatory and noninflammatory lesions relative to vehicle lotion, with low potential for cutaneous irritation. ...

see more →

Guidelines  29 results

Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers
https://www.foamix.com/news-releases/news-release-details/update-foamix-receives-fda-approval-amzeeqtm-topical-minocycline

Oct 17th, 2019 - Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved its novel AMZEEQTM (minocycline) topical foam, 4%. AMZEEQ, fo...

Acne Vulgaris: Diagnosis and Treatment
https://www.aafp.org/afp/2019/1015/p475.html
American Family Physician;

Oct 14th, 2019 - Acne vulgaris is the most prevalent chronic skin disease in the United States, affecting nearly 50 million people per year, mostly adolescents and young adults. Potential sequelae of acne, such as scarring, dyspigmentation, and low self-esteem, ma...

FDA approves Aklief for acne on face, trunk
https://www.healio.com/dermatology/acne/news/online/%7Bcc693b23-e6fc-4919-a303-fc14f62279b4%7D/fda-approves-aklief-for-acne-on-face-trunk

Oct 3rd, 2019 - The FDA recently approved Galderma’s topical retinoid cream, known as Aklief, for the treatment of acne vulgaris. Additionally, the company reported positive safety profiles for Aklief in two phase 3 clinical trials on acne of both the face and tr...

Oral isotretinoin for acne
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009435.pub2/full
Riera,R.,etal

Nov 23rd, 2018 - Acne vulgaris, a chronic inflammatory disease of the pilosebaceous unit associated with socialisation and mental health problems, may affect more than 80% of teenagers. Isotretinoin is the only drug that targets all primary causal factors of acne;...

Acne Vulgaris - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK459173/
Sutaria,A.,et al

Nov 13th, 2018 - Acne vulgaris is an inflammatory disorder of pilosebaceous unit, which runs a chronic course and it is self-limiting. Acne vulgaris is triggered by Propionibacterium acnes in adolescence, under the influence of normal circulating dehydroepiandrost...

see more →

Drugs  663 results see all →

Clinicaltrials.gov  3,493 results

An overview of sarecycline for the treatment of moderate-to-severe acne vulgaris.
https://doi.org/10.1080/14656566.2020.1813279
Expert Opinion on Pharmacotherapy; Valente Duarte de Sousa IC

Sep 14th, 2020 - Sarecycline is a novel, tetracycline-class antibiotic specifically designed to treat inflammatory acne. It offers a narrow spectrum of activity (mainly against Cutinebacterium acnes), and it shows less in vitro activity than other tetracyclines ag...

Fighting acne for the fighting forces.
https://doi.org/10.12788/cutis.0057
Cutis Brahe C, Peters K

Sep 11th, 2020 - Acne vulgaris is one of the most common dermatologic diseases, ranging from comedonal or inflammatory papules to large, painful, disfiguring cysts. Numerous treatment approaches are available, each with their own risks and benefits that must be we...

Tolerability of tretinoin lotion 0.05% for moderate to severe acne vulgaris: a post hoc...
https://doi.org/10.12788/cutis.0059
Cutis Bhatia ND, Werschler WP et. al.

Sep 11th, 2020 - Acne vulgaris (acne) is the most common dermatologic disorder seen in black patients. However, data are lacking on the effects of treatments, such as topical retinoids. Acne in black patients is frequently associated with postinflammatory hyperpig...

The Effect of Isotretinoin on Oocyte Maturation in Adolescent Female Rats.
https://doi.org/10.1159/000510031
Gynecologic and Obstetric Investigation; Kacamak P, Ozogul C et. al.

Sep 7th, 2020 - Isotretinoin is used in acne vulgaris treatment for more than 20 years. Isotretinoin has serious side effects on many organs, but there are no comprehensive studies investigating its possible toxic effects on reproductive organs. Thus, we aimed to...

The Effects of Once-Daily Tretinoin 0.05% Lotion on Quality of Life in Patients with Mo...
https://doi.org/10.1007/s40257-020-00559-3
American Journal of Clinical Dermatology; Tyring SK, Kircik L et. al.

Sep 4th, 2020 - In two phase III clinical trials of patients with moderate-to-severe acne (NCT02932306, NCT02965456), tretinoin 0.05% lotion reduced inflammatory and noninflammatory lesions relative to vehicle lotion, with low potential for cutaneous irritation. ...

see more →

News  253 results

CUTIS Celebrates 55 Years
https://www.mdedge.com/dermatology/article/217608/cutis-celebrates-55-years

Feb 20th, 2020 - When the first issue of Cutis was published in February 1965: Alopecia was featured on the cover Eugene F. Traub, MD, was Chief Editor, and John T.

Product News February 2020
https://www.mdedge.com/dermatology/article/217153/product-news-february-2020

Feb 12th, 2020 - Arazlo Lotion Approved for Acne Vulgaris Ortho Dermatologics announces US Food and Drug Administration approval of Arazlo (tazarotene) Lotion 0. 045% for the topical treatment of acne vulgaris in patients 9 years and older.

Product News November 2019
https://www.mdedge.com/dermatology/article/211999/psoriasis?channel=38029

Nov 11th, 2019 - Aklief Cream Topical Retinoid Approved for Acne Vulgaris Galderma Laboratories, LP, announces US Food and Drug Administration approval of Aklief (trifarotene) Cream 0. 005% for the treatment of acne vulgaris in patients 9 years and older.

FDA approves minocycline foam for moderate, severe acne
https://www.mdedge.com/internalmedicine/article/210605/acne/fda-approves-minocycline-foam-moderate-severe-acne?channel=39313
Lucas Franki

Oct 22nd, 2019 - The Food and Drug Administration has approved topical minocycline (Amzeeq) foam, 4%, for the treatment of inflammatory lesions associated with nonnodular moderate to severe acne vulgaris in adults and pediatric patients aged at least 9 years. Oliv.

Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers
https://www.foamix.com/news-releases/news-release-details/update-foamix-receives-fda-approval-amzeeqtm-topical-minocycline

Oct 17th, 2019 - Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved its novel AMZEEQTM (minocycline) topical foam, 4%. AMZEEQ, fo...

see more →